Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
نویسندگان
چکیده
منابع مشابه
Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
Triple-negative breast cancer (TNBC), a subtype distinguished by negative immunohistochemical assays for expression of the estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2(HER2) represents 15% of all breast cancers. Patients with TNBC generally experience a more aggressive clinical course with increased risk of disease progression and poorer overall survi...
متن کاملTriple-Negative Breast Cancer: Frequency, Molecular Subtypes, and Therapeutic Options
INT RO DUC TI ON Breast cancer is the most common malignancy in women. An estimated 1 million cases of breast cancer are diagnosed annually worldwide and 400.000 patients die from the disease every year[1]. Multiple oncogenes, tumor suppressor genes, and sex steroid hormones and their receptors are involved in the genesis and development of breast cancer. Breast cancer is a heterogeneous malign...
متن کاملManagement Options in Triple-Negative Breast Cancer
Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this re...
متن کاملTreatment options for patients with triple-negative breast cancer
Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainl...
متن کاملTreatment Options for Triple-negative Breast Cancers
grade (severity). Identification of molecular markers such as expression of the estrogen (er) and progesterone receptors (pgr) and the human epidermal growth factor receptor 2 (her2) has offered additional predictive value for the therapeutic assessment of women diagnosed with breast cancer 1–4. More recently, gene expression analysis using dna microarray technology has identified additional br...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chemotherapy Research and Practice
سال: 2011
ISSN: 2090-2107,2090-2115
DOI: 10.1155/2011/696208